Info 🌱 來自:test TLDR_brignole2018ESCGuidelines2018 Kim. 2019. 1529P - Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19) TLDR_kim_1529p_2019